Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ -11.00K |
| Operating Income | $ -142.26M | $ -104.96M | $ -106.99M | $ -71.49M | $ -21.53M |
| EBITDA | $ -141.87M | $ -104.58M | $ -106.63M | $ -71.33M | $ -21.52M |
| Net Income | $ -129.47M | $ -96.66M | $ -104.79M | $ -71.10M | $ -22.12M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 434.09M | $ 261.81M | $ 204.42M | $ 287.25M | $ 338.55M |
| Total Assets | $ 450.98M | $ 276.94M | $ 215.65M | $ 295.94M | $ 342.72M |
| Total Debt | $ 1.43M | $ 2.42M | $ 2.56M | $ 3.29M | $ 0.00 |
| Net Debt | $ -138.05M | $ -66.12M | $ -21.14M | $ -10.52M | $ -338.55M |
| Total Liabilities | $ 42.02M | $ 23.05M | $ 18.10M | $ 11.38M | $ 4.58M |
| Stockholders' Equity | $ 408.96M | $ 253.90M | $ 197.55M | $ 284.57M | $ 338.14M |
| Cash Flow | |||||
| Free Cash Flow | $ -104.51M | $ -83.73M | $ -82.43M | $ -52.27M | $ -19.92M |
| Operating Cash Flow | $ -104.35M | $ -83.73M | $ -82.06M | $ -50.69M | $ -19.87M |
| Investing Cash Flow | $ -93.53M | $ -4.85M | $ 91.48M | $ -275.44M | $ -56.00K |
| Financing Cash Flow | $ 268.82M | $ 133.41M | $ 476.00K | $ 1.39M | $ 358.40M |